Review
Copyright ©The Author(s) 2023.
World J Clin Cases. Jul 6, 2023; 11(19): 4458-4476
Published online Jul 6, 2023. doi: 10.12998/wjcc.v11.i19.4458
Table 1 Types of regulation of serotonergic (5-Hydroxytryptamine) pathway by specific enteric microbiota in gastrointestinal tract
Microbiota spp.
5-HT pathway
Mechanisms of action and observations
Ref.
Akkermansia muciniphila (Amuc_1100)Upregulation Promote intestinal 5-HT biosynthesis and extracellular availability through TLR2 signalling[129]
Akkermansia muciniphila (extracellular vesicles)UpregulationIncrease expression of the Htr4 gene, and decreases expression of the Htr2B, Htr3B, and Htr7 genes[129]
Bacteriodes thetaiotaomicronUpregulationRestore 5-HT+ EC cells and shape EC networks in the GI tract of GF mice by producing SCFAs[130]
Bifidobacterium dentiumUpregulationIncrease intestinal 5-HT level; expressions of 5-HTra receptors 2a and 4, and SERT by producing acetate[131]
Bifidobacterium longum andDownregulationUpregulate SERT expression[132]
Lactobacillus acidophilus
Bifidobacterium pseudolongumDownregulationDiminish EC cells[133]
Clostridium ramosumUpregulationPromote 5-HT synthesis in colonic EC cells and program differentiation of intestinal stem progenitors toward a secretory 5-HT-producing lineage[134]
Corynebacterium spp., Enterococcus spp., Streptococcus spp.UpregulationEnable the direct production of 5-HT[135]
Escherichia coli Nissle 1917UpregulationEnhance 5-HT bioavailability in ileal tissue through interaction with compounds secreted from host tissue[136]
Indigenous spore-forming bacteriaUpregulationEnhance colonic 5-HT pathway by upregulation of Htr4[137]
Lactobacillus acidophilusDown regulation Upregulate SERT expression[138]
Lactobacillus plantarum IS-10506UpregulationIncrease gut 5-HT production along with brain 5-HTT, neurotrophin, and brain-derived neurotrophic factor[139]
Lactobacillus plantarum PS128UpregulationIncrease 5-HT+ cells in the gut and alter expression levels of Tph1, Chga, Slc6a4, and Htr4[140]
Lactobacillus rhamnosusDown regulationUpregulate gene and protein level of SERT[141]
SadA-expressing Staphylococci, Trichinella spiralis and Campylobacter jejuni (pathogens)UpregulationPromote converting 5-HTP into 5-HT; increase EC cell number and reduce SERT expression[141]
Table 2 Various therapies prescribed for the treatment of irritable bowel syndrome along with their possible mode of action
Therapy
Description
Proposed mechanism(s) of action
PrebioticsIngested compounds targeted to stimulate gut microbiotaMechanism of action undefined, but may include: Anti-inflammatory effects; inhibition of pathogen adherence; and growth of intestinal mucosal layer
ProbioticsIngested microorganisms (e.g., bacteria)Mechanism of action undefined, but may include: Inhibition of pathogenic microorganism colonization; support intestinal barrier integrity and function; production of beneficial micronutrients; and activation and augmentation of the enteric nervous system
RifaximinNonabsorbable, bile-soluble antibiotic indicated for the treatment of adults with IBS-DAntibacterial against Gram-positive and Gram-negative bacteria: Modulation of gut-immune signalling; inhibition of bacterial translocation; SIBO eradication (in some patients); causing decreases in GI methane concentrations in combination; and with the antibiotic neomycin (in patients with IBS-C)
SBIPrescription medical food for patients with IBS-DModulation of gut microbiota: Causing decreases in GI permeability
SYN-010Derivative of the HMG-CoA reductase inhibitor lovastatin lactone; currently in development for the treatment of patients with IBS-CInhibition of methane production by Methanobrevibacter smithii
Dietary modificationVariable; one example is the low FODMAP dietCausing decreases in GI gas production
Causing decreases in intra-luminal fluid production